- Trials with a EudraCT protocol (4,282)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,282 result(s) found for: Diagnostic test.
Displaying page 14 of 215.
| EudraCT Number: 2020-002190-10 | Sponsor Protocol Number: UCDCRC/20/03 | Start Date*: 2021-02-05 |
| Sponsor Name:University College Dublin | ||
| Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) | ||
| Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-005112-17 | Sponsor Protocol Number: IRFMN-BRC-7103 | Start Date*: 2017-07-11 | |||||||||||
| Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
| Full Title: Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study | |||||||||||||
| Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003926-10 | Sponsor Protocol Number: CHUBX2017/32 | Start Date*: 2019-02-13 | |||||||||||
| Sponsor Name:CHU de Bordeaux | |||||||||||||
| Full Title: Prospective comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the initial work-up of Multiple Myeloma | |||||||||||||
| Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-004420-15 | Sponsor Protocol Number: M21IDB | Start Date*: 2021-11-30 |
| Sponsor Name:NKI-AVL | ||
| Full Title: A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade) | ||
| Medical condition: Urothelial cell carcinoma of the bladder | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000685-11 | Sponsor Protocol Number: PR-30-5011-C | Start Date*: 2013-09-29 | |||||||||||
| Sponsor Name:TESARO Inc. | |||||||||||||
| Full Title: A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer | |||||||||||||
| Medical condition: Platinum Sensitive Ovarian Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: SE (Completed) DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) HU (Completed) ES (Ongoing) BE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005921-31 | Sponsor Protocol Number: V00079 CR 402 | Start Date*: 2008-07-01 | |||||||||||
| Sponsor Name:Pierre Fabre Médicament | |||||||||||||
| Full Title: Evaluation du pouvoir bactériostatique de la préparation V0079CR CETAVLON sur la flore cutanée au niveau des mains. Etude preuve de concept. | |||||||||||||
| Medical condition: Evolution de la flore cutanée au niveau des mains après application du produit | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003252-24 | Sponsor Protocol Number: 53718678RSV2004 | Start Date*: 2018-01-16 | |||||||||||
| Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
| Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le... | |||||||||||||
| Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002224-40 | Sponsor Protocol Number: OAM4971g | Start Date*: 2012-05-14 | |||||||||||||||||||||
| Sponsor Name:Genentech, Inc. | |||||||||||||||||||||||
| Full Title: A randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with Tarceva® (erlotinib) in Patients with Me... | |||||||||||||||||||||||
| Medical condition: MET DIAGNOSTIC−POSITIVE NON−SMALL CELL LUNG CANCER (NSCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) ES (Completed) DE (Completed) HU (Completed) IE (Completed) NL (Completed) GB (Completed) IT (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2006-002274-22 | Sponsor Protocol Number: MH-127 | Start Date*: 2006-12-18 | |||||||||||
| Sponsor Name:Bracco Imaging S.p.A. | |||||||||||||
| Full Title: A PHASE IIIB, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE 0.1 MMOL/KG OF MULTIHANCE® WITH 0.1 MMOL/KG OF MAGNEVIST® FOR CONTRAST-ENHANCED MAGNETIC RESONANCE ANGIOGRAPHY (CE-... | |||||||||||||
| Medical condition: Subjects with moderate-to-severe peripheral arterial disease based on the Fontaine’s staging of peripheral arterial occlusive disease classes IIb, III and IV | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-008301-22 | Sponsor Protocol Number: 1661/08 | Start Date*: 2010-03-05 | |||||||||||
| Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
| Full Title: PHASE II CLINICAL STUDY OF THE DIAGNOSTIC EFFICACY OF [18F]FLUOROETHYILCHOLINE ([18F]FECh) IN PATIENTS WITH PROSTATE CANCER | |||||||||||||
| Medical condition: PROSTATE CANCER | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005917-35 | Sponsor Protocol Number: CMC-P014 | Start Date*: 2012-03-20 | |||||||||||
| Sponsor Name:CMC Contrast AB | |||||||||||||
| Full Title: Accuracy in Diagnosis of Focal Liver Lesions following Oral Administration of CMC-001 Combined with Diffusion Weighted Magnetic Resonance Imaging (MRI) of the Liver. An Open-Label, Non-Randomised, ... | |||||||||||||
| Medical condition: Focal Liver Lesions in Diagnosed Cancer Patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-000586-45 | Sponsor Protocol Number: S56327 | Start Date*: 2014-05-08 | |||||||||||
| Sponsor Name:KU Leuven | |||||||||||||
| Full Title: Oxytocin-based pharmacotherapy for Autism Spectrum Disorders: Investigating the neural and behavioral effects of a promising intervention approach | |||||||||||||
| Medical condition: Young male adults with Autism Spectrum Disorders (18-30 years) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003339-39 | Sponsor Protocol Number: EHDA-01 | Start Date*: 2017-05-03 | |||||||||||
| Sponsor Name:JOSÉ MARÍA PALAZÓN AZORÍN | |||||||||||||
| Full Title: A randomized, controlled and double-blind trial of intravenous azithromycin versus intravenous erythromycin as a single dose prior to endoscopy in upper gastrointestinal bleeding | |||||||||||||
| Medical condition: Upper gastrointestinal haemorrhage | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-013476-53 | Sponsor Protocol Number: PHRC-N/2009/POK-01 | Start Date*: 2010-09-02 |
| Sponsor Name:CHU de Nîmes | ||
| Full Title: Evaluation des performances de l’imagerie cérébrale isotopique du métabolisme glucidique en TEP (18F-FDG) et de la perfusion en TEMP (99mTc-ECD) pour le diagnostic de maladie d’Alzheimer au stade p... | ||
| Medical condition: Maladie d'alzheimer au stade prodromal | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-002495-18 | Sponsor Protocol Number: SG2006/1 | Start Date*: 2007-04-08 | |||||||||||
| Sponsor Name:Wrightington, Wigan and Leigh NHS Trust | |||||||||||||
| Full Title: The use of ketamine in combination with midazolam for the induction of conscious sedation during endoscopic retrograde cholangiopancreatography (ERCP). | |||||||||||||
| Medical condition: The study will not investigate any specific disease, but rather the sedation techniques used for endoscopic retrograde cholangiopancreatography, a form of endoscopy which can be used to diagnose an... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002132-25 | Sponsor Protocol Number: 12-181 | Start Date*: 2015-06-29 |
| Sponsor Name:University Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty | ||
| Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial | ||
| Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000652-11 | Sponsor Protocol Number: SPAGOPIX-02 | Start Date*: 2022-08-17 | |||||||||||
| Sponsor Name:Spago Nanomedical AB | |||||||||||||
| Full Title: A Phase IIa, single centre, open label, proof of concept study concerning efficacy of the novel intravenous contrast agent SN132D in patients with suspected endometriosis. | |||||||||||||
| Medical condition: Suspected endometriosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-002846-51 | Sponsor Protocol Number: P070703 | Start Date*: 2008-07-15 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: Etude de l'efficacité du Rituximab versus Azathioprine en traitement d'entretien au cours des vascularites associées aux ANCA : Etude prospective, multicentrique, contrôlée, randomisée | |||||||||||||
| Medical condition: Patients atteints de vascularites associées aux ANCA : GW, MPA et formes rénales limitées (glomérulonéphrite pauci-immune), avec ou sans ANCA (au diagnostic comme à la rémission). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-004054-24 | Sponsor Protocol Number: PHRCN2017/CAPRI-MARIE/NK | Start Date*: 2019-03-18 | |||||||||||
| Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy | |||||||||||||
| Full Title: Assessment of the (18)F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis | |||||||||||||
| Medical condition: cardiac amyloidosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002016-27 | Sponsor Protocol Number: 69HCL18_0265 | Start Date*: 2018-08-28 | |||||||||||
| Sponsor Name:HOSPICES CIVILS DE LYON | |||||||||||||
| Full Title: Diagnostic par TEP-IRM de la pseudoprogression tumorale chez des patients porteurs d’un glioblastome traités par radiochimiothérapie concomitante et adjuvante avec du temozolomide TIGRE (TepIrmGli... | |||||||||||||
| Medical condition: glioblastomes traités par radiochimiothérapie avec du temozolomide. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.